Gapping up
In reaction to earnings/guidance:
- ARCB +4.6%, TSEM +4.5%, UUUU +2.9%, GPN +1.3%
Other news:
- XCUR +36.3% (Exicure and Ipsen enter collaboration targeting rare neurodegenerative disorders)
- BPTS +22.7% (reports top line results of SARA-INT Phase 2 study)
- LPG +5.8% (increases dividend to $1.00/sh from $0; also updated operating outlook)
- XPEV +4.4% (July deliveries)
- LI +4% (July deliveries)
- EDU +3.7% (bouncing from last week's weakness)
- FOLD +2.3% (announces that the European Commission has approved Galafold)
- ABCM +2% (to acquire BioVision for $340 mln)
- TAL +2% (bouncing from last week's weakness)
- ALKS +1.3% (FDA granted Fast Track designation to nemvaleukin alfa (nemvaleukin) for the treatment of mucosal melanoma)
- MSCI +0.7% (entered into a definitive agreement to acquire Real Capital Analytics for $950 mln in cash)
Analyst comments:
- BLMN +3.9% (upgraded to Buy from Hold at Deutsche Bank)
- FSLR +3.2% (upgraded to Positive from Neutral at Susquehanna)
- GSKY +2.7% (upgraded to Equal-Weight from Underweight at Stephens)
- AB +1.5% (upgraded to Buy from Neutral at Citigroup)
- AVTR +1.5% (upgraded to Overweight from Neutral at Piper Sandler)